Endo Pharmaceuticals (ENDP) updated its FY13 earnings guidance on Thursday. The company provided EPS guidance of $4.40-4.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.51. The company issued revenue guidance of $2.80-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

A number of research firms have also recently commented on ENDP. Analysts at Piper Jaffray downgraded shares of Endo Pharmaceuticals from a neutral rating to an underweight rating in a research note to investors on Monday. They now have a $22.00 price target on the stock, down previously from $28.00. On a related note, analysts at RBC Capital downgraded shares of Endo Pharmaceuticals from a sector perform rating to an underperform rating in a research note to investors on Thursday, February 7th. They now have a $24.00 price target on the stock, down previously from $25.00. Finally, analysts at Needham & Company reiterated an underperform rating on shares of Endo Pharmaceuticals in a research note to investors on Thursday, January 31st.

Nine research analysts have rated the stock with a buy rating, nine have given a hold rating, one has assigned an underweight rating, and two have issued a sell rating to the company’s stock. Endo Pharmaceuticals has an average rating of overweight and a consensus price target of $32.54.

Endo Pharmaceuticals (ENDP) traded up 0.65% on Thursday, hitting $31.00. Endo Pharmaceuticals (ENDP) has a 1-year low of $25.01 and a 1-year high of $39.29. The stock’s 50-day moving average is currently $28.77. The company has a market cap of $3.537 billion and a price-to-earnings ratio of 287.85.

Endo Pharmaceuticals last announced its earnings results on Thursday, February 28th. The company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.08. The company had revenue of $801.06 million for the quarter, compared to the consensus estimate of $807.98 million. During the same quarter in the previous year, the company posted $1.40 earnings per share. The company’s revenue for the quarter was down .3% on a year-over-year basis. Endo Pharmaceuticals has set its FY13 guidance at $4.40-4.70 EPS. Analysts expect that Endo Pharmaceuticals (ENDP) will post $4.96 EPS for the current fiscal year.

Endo Health Solutions Inc., formerly Endo Pharmaceuticals Holdings Inc., is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.